McKesson Acquisitions: How McKesson Built Its Business Through M&A

McKesson acquisitions show how one of America’s most important healthcare distribution companies used M&A to expand across pharmaceutical distribution, medical supplies, oncology services, healthcare software, pharmacy technology, retail pharmacy, care management, and administrative support.

From 1990 to 2024, McKesson completed 21 acquisitions with a total disclosed deal value of about $36.1 billion and an average disclosed deal size of roughly $1.7 billion. The company’s acquisition activity has focused primarily on health care, pharmaceutical services, and software. Health care accounts for 13 deals, pharmaceutical businesses account for 6, and software accounts for 5.

That pattern is important. McKesson has not used acquisitions only to become a larger distributor. It has used M&A to move deeper into the systems that surround drug access, provider workflows, oncology care, pharmacy operations, medical supply distribution, and patient support.

The most recent listed acquisition is Core Ventures, announced in August 2024 for about $2.5 billion. Core Ventures is a business and administrative services corporation founded by Florida Cancer Specialists & Research Institute. McKesson’s agreement involved acquiring an approximately 70% controlling interest, with Florida Cancer Specialists physicians retaining about 30%.

What Is McKesson?

McKesson distributes medical supplies, information technology, and care management products and services. Its business sits at the center of the healthcare supply chain, connecting pharmaceutical manufacturers, pharmacies, healthcare providers, clinics, hospitals, specialty practices, and patients.

The company is best known as a major healthcare distributor, but its acquisition record shows a much broader business model. McKesson has invested in drug distribution, oncology networks, healthcare technology, pharmacy benefit tools, medical imaging software, medical-surgical supplies, drugstore operations, and administrative services.

This matters because modern healthcare is not only about moving products from manufacturer to provider. It also depends on data, reimbursement, prior authorization, patient affordability, specialty care management, provider administration, and cost control.

McKesson’s acquisition history reflects that reality. The company has repeatedly purchased businesses that help it control more of the infrastructure surrounding medicine access and care delivery.

Why McKesson Acquisitions Matter

McKesson acquisitions matter because they show how healthcare distribution has evolved from a logistics business into a broader healthcare services platform.

In the past, a distributor’s primary role was to move medicines and supplies efficiently. That role still matters. However, healthcare has become more complex. Specialty drugs are expensive. Oncology care requires coordination. Providers need technology tools. Pharmacies need support with coverage and reimbursement. Patients need help affording prescriptions.

McKesson’s acquisitions respond to these pressures. The company has bought oncology assets, pharmacy technology platforms, prescription savings software, medical supply distributors, healthcare services companies, and information systems providers.

The result is a business model that reaches beyond wholesale distribution. McKesson has become involved in the financial, administrative, clinical, and technology layers that support healthcare delivery.

That makes McKesson acquisitions important for investors, healthcare executives, pharmacies, providers, and policy observers. They show where value is shifting in healthcare: toward specialty care, data, affordability tools, administrative services, and integrated provider networks.

Full List of McKesson Acquisitions

The table below summarizes 20 of the listed McKesson acquisitions, including deal value, announcement date, main category, and strategic value.

McKesson Acquisitions Timeline

1998: A Major Move Into Healthcare Software and Supplies

McKesson’s listed acquisition history includes two important transactions in 1998: RedLine HealthCare and HBO & Company.

RedLine HealthCare gave McKesson additional medical supplies and services exposure in the extended-care industry. HBO & Company was far larger, valued at $14.1 billion. It made information systems for clinical, financial, billing, physician practice, and medical records software.

The HBO & Company deal remains the largest listed acquisition in McKesson’s record. It shows that McKesson recognized early that healthcare technology would become central to provider operations, billing, medical records, and clinical administration.

2000: Patient Web Interfaces

In 2000, McKesson acquired MediVation for $38.0 million. MediVation provided a provider-patient interface that enabled providers to transfer data to secure patient web pages.

This deal fits the early digital health theme. At the time, secure online healthcare communication was still developing. McKesson’s acquisition showed interest in patient-facing digital tools before many modern healthcare portals became standard.

2002: Medical Imaging Networks

In 2002, McKesson acquired A.L.I. Technologies for $340.0 million. The company provided digital image network systems for medicine.

This acquisition strengthened McKesson’s position in healthcare information technology. Medical imaging is central to diagnosis, specialist workflows, and hospital operations. By acquiring A.L.I. Technologies, McKesson added deeper capability in medical image management.

2004: Medical-Surgical Distribution

In 2004, McKesson acquired Moore Medical for $40.0 million. Moore Medical was an internet-enabled, multi-channel marketer and distributor of medical-surgical and pharmaceutical products.

This deal aligned closely with McKesson’s distribution roots. It expanded the company’s reach in medical-surgical products and strengthened its ability to serve healthcare customers through multiple channels.

2005: Cardiac Imaging and Information Management

In 2005, McKesson acquired Medcon for $105.0 million. Medcon was a global leader in cardiac image and information management solutions.

This acquisition added specialized healthcare IT capability in cardiology. It also reinforced the idea that McKesson was not only buying distribution businesses. It was acquiring technology that helped providers manage clinical information.

2007: Healthcare Services and Oncology Distribution

McKesson made two notable acquisitions in 2007: Per-Se Technologies and Oncology Therapeutics Network.

Per-Se Technologies was acquired for $1.8 billion. It expanded McKesson’s healthcare services capabilities, especially in administrative and revenue-related areas. Oncology Therapeutics Network, acquired for $519.0 million, added oncology-related distribution and medical infrastructure.

This period marked an important shift toward specialty healthcare. Oncology is one of the most complex and expensive areas of medicine, making distribution, reimbursement, provider support, and patient management especially important.

2008: Wholesale Drug Distribution

In 2008, McKesson acquired McQueary Brothers for $190.0 million. McQueary Brothers operated as a wholesale drug company serving pharmacies.

This was a direct extension of McKesson’s core distribution business. It strengthened the company’s pharmacy supply network and reinforced its position in drug distribution.

2010: Community Oncology With US Oncology

In 2010, McKesson acquired US Oncology for $2.1 billion. US Oncology operated a network of integrated community-based oncology practices providing cancer care services in the United States.

This was one of McKesson’s most strategically important acquisitions. It expanded the company’s role in community oncology, a market where drug distribution, care coordination, reimbursement, specialty treatment, and provider support are closely linked.

The deal also helped McKesson build a platform that would remain central to later oncology-related acquisitions.

2012: Canadian Pharmacy Network

In 2012, McKesson acquired Drug Trading Company Limited for $916.8 million. Drug Trading operated an integrated retail pharmacy network in Canada.

This acquisition strengthened McKesson’s Canadian pharmacy presence and added retail pharmacy network exposure. It also demonstrated the company’s international and cross-border interest in pharmaceutical services.

2013: Medical Products and International Pharmaceutical Logistics

In 2013, McKesson acquired PSS World Medical and Celesio. PSS World Medical, acquired for $1.5 billion, distributed medical products, equipment, billing services, and pharmaceutical-related products. Celesio, acquired for $5.4 billion, provided logistics and services in the pharmaceutical and healthcare sector across 16 countries.

Celesio was a major international expansion deal. It gave McKesson a much larger global pharmaceutical logistics and services footprint.

PSS World Medical expanded the company’s medical products distribution capabilities. Together, the deals strengthened McKesson’s role across both pharmaceutical and medical product supply chains.

2015: Healthcare Services Expansion

In 2015, McKesson acquired UDG Healthcare for $460.7 million. UDG Healthcare provided clinical, commercial, communication, and packaging services.

This deal expanded McKesson’s healthcare services capabilities beyond pure distribution. It added services that support pharmaceutical companies and healthcare organizations in commercial and operational areas.

2016: Oncology, Biopharma Support, and Canadian Retail Pharmacy

McKesson completed three important acquisitions in 2016: Biologics, Rexall, and Vantage Oncology.

Biologics, acquired for $1.2 billion, provided a patient-focused platform for managing the financial, emotional, and physical burdens of cancer treatment. Rexall, acquired for $2.1 billion, was a Canadian drugstore operator. Vantage Oncology, acquired for $525.0 million, offered development, implementation, and management solutions for radiation oncology.

This year was critical to McKesson’s healthcare strategy. It deepened the company’s exposure to oncology, specialty care, patient support, and retail pharmacy operations.

2017: Prior Authorization Technology With CoverMyMeds

In 2017, McKesson acquired CoverMyMeds for $1.1 billion. CoverMyMeds is a healthcare technology platform that helps doctors and pharmacists complete prior authorization and insurance coverage determination forms for drugs.

This acquisition was strategically important because prior authorization is one of the most burdensome administrative processes in healthcare. By acquiring CoverMyMeds, McKesson gained a technology platform that sits directly in the workflow between providers, pharmacies, payers, and patients.

It also strengthened McKesson’s position in healthcare software.

2022: Prescription Savings Technology

In 2022, McKesson acquired Rx Savings Solutions for $875.0 million. Rx Savings Solutions provides healthcare consumerism software to help employers and employees save money on prescription medications.

This acquisition aligned with rising concern about drug affordability. Employers, patients, and plan sponsors increasingly need tools that identify lower-cost medication options.

Rx Savings Solutions gave McKesson another software platform tied to prescription access, affordability, and patient decision-making.

2024: Core Ventures and Oncology Administration

In August 2024, McKesson announced its agreement to acquire an approximately 70% controlling interest in Core Ventures for about $2.49 billion. Core Ventures was established by Florida Cancer Specialists & Research Institute and provides business and administrative services. McKesson later said the acquisition closed in June 2025.

This deal strengthened McKesson’s oncology platform. Florida Cancer Specialists remained independently owned and became a member of McKesson’s The US Oncology Network, according to McKesson’s announcement.

The acquisition reflects McKesson’s continuing strategy of expanding community-based oncology support, provider administration, and specialty care infrastructure.

Biggest McKesson Acquisitions by Deal Value

McKesson’s largest acquisitions show how the company has made major bets on healthcare software, pharmaceutical logistics, oncology, retail pharmacy, and medical distribution.

The top deals show McKesson’s evolution. Earlier large acquisitions emphasized healthcare information systems and distribution scale. Later deals increasingly focused on specialty care, pharmacy services, oncology, and patient support.

Most Common Acquisition Categories

McKesson acquisitions are concentrated in health care, pharmaceuticals, software, medical services, and information technology.

This category mix shows that McKesson’s M&A strategy is centered on the healthcare economy. The company has used acquisitions to strengthen both the physical distribution of healthcare products and the digital systems that support care delivery.

Strategic Lessons From McKesson Acquisitions

Distribution Can Evolve Into Services

McKesson acquisitions show how a distributor can move into services that sit around its core supply chain. The company did not stop at moving drugs and supplies. It expanded into oncology networks, provider support, pharmacy software, prescription savings, medical imaging, and administrative services.

This evolution helps McKesson become more embedded in healthcare operations.

Oncology Became a Strategic Priority

US Oncology, Oncology Therapeutics Network, Vantage Oncology, Biologics, and Core Ventures all point to oncology as a major theme.

Cancer care is complex, expensive, and highly dependent on specialty drugs and coordinated support. McKesson’s oncology acquisitions position the company closer to providers, patients, and specialty medication workflows.

Healthcare Software Supports Access and Affordability

CoverMyMeds and Rx Savings Solutions show how software can improve prescription access and affordability. These platforms address administrative friction and cost barriers that affect patients, employers, providers, pharmacies, and payers.

For McKesson, software acquisitions help create value beyond physical distribution.

How McKesson Acquisitions Fit Its Business Model

McKesson’s business model is built around healthcare distribution, medical supplies, information technology, and care management products and services. Its acquisitions fit that model because they expand the company’s role in the systems that move, pay for, prescribe, and support healthcare products.

A drug distributor benefits when it can serve pharmacies efficiently. But it may gain more strategic value when it also supports provider networks, handles specialty care workflows, helps patients access medications, and provides software used in prescription processes.

That is the logic behind many McKesson acquisitions. Celesio expanded international pharmaceutical logistics. PSS World Medical expanded medical product distribution. US Oncology and Core Ventures strengthened oncology infrastructure. CoverMyMeds and Rx Savings Solutions added healthcare software. Rexall and Drug Trading expanded retail pharmacy exposure.

Together, these deals show McKesson building an ecosystem around medication access and healthcare delivery.

Financial and Ownership Context

McKesson completed 21 acquisitions from 1990 to 2024, with total disclosed value of about $36.1 billion and an average disclosed deal size of approximately $1.7 billion.

The average is heavily influenced by large transactions, especially HBO & Company at $14.1 billion and Celesio at $5.4 billion. The Core Ventures transaction, valued at about $2.49 billion for a controlling interest, is also one of the largest listed deals in McKesson’s history.

This financial pattern shows that McKesson has been willing to make large strategic commitments when a transaction supports its healthcare platform. However, the company has also completed smaller acquisitions, such as Moore Medical, MediVation, and Medcon, that added targeted capabilities.

The mix of large platform deals and smaller capability-building acquisitions is central to McKesson’s M&A strategy.

Competitive Impact of McKesson Acquisitions

McKesson acquisitions have strengthened the company’s competitive position in several ways.

First, they expanded the company’s scale in pharmaceutical and medical supply distribution. Celesio, PSS World Medical, Moore Medical, McQueary Brothers, and Drug Trading all supported distribution reach.

Second, acquisitions helped McKesson build a powerful oncology platform. US Oncology, Vantage Oncology, Oncology Therapeutics Network, Biologics, and Core Ventures all connect to cancer care.

Third, software acquisitions improved McKesson’s presence in healthcare workflows. HBO & Company, A.L.I. Technologies, Medcon, CoverMyMeds, and Rx Savings Solutions all supported digital or administrative healthcare functions.

Fourth, the company’s acquisitions increased its relevance to multiple stakeholders: pharmacies, providers, oncology practices, drug manufacturers, employers, and patients.

The competitive impact is significant because healthcare distribution is a scale-driven industry. Companies that can combine logistics, technology, services, and specialty care infrastructure may have stronger relationships across the healthcare system.

Advantages of the Acquisition Strategy

Stronger Healthcare Ecosystem

McKesson’s acquisitions expanded the company from distribution into oncology care, technology, pharmacy services, and healthcare administration.

Greater Oncology Exposure

The company built a meaningful oncology platform through several acquisitions. This gives McKesson exposure to one of the most important specialty care categories.

More Software Capability

CoverMyMeds, Rx Savings Solutions, HBO & Company, A.L.I. Technologies, Medcon, and MediVation show how McKesson used M&A to strengthen healthcare technology.

Expanded Distribution Scale

Celesio, PSS World Medical, Drug Trading, Moore Medical, and McQueary Brothers expanded McKesson’s supply chain and distribution reach.

Better Positioning Around Drug Access

Several deals address medication access, affordability, authorization, pharmacy operations, and specialty care support.

Disadvantages of the Acquisition Strategy

Regulatory Scrutiny

Healthcare acquisitions can attract regulatory attention, especially when they involve provider networks, drug distribution, pharmacy services, or large-scale healthcare administration.

Integration Complexity

McKesson’s acquisitions span software, distribution, oncology, retail pharmacy, medical supplies, and administrative services. Integrating such different businesses can be difficult.

Healthcare Policy Risk

Drug pricing, reimbursement rules, pharmacy regulation, oncology payment models, and healthcare policy changes can affect performance.

Large Deal Risk

Major acquisitions such as HBO & Company, Celesio, Core Ventures, Rexall, and US Oncology require strong execution to justify their purchase prices.

Public Perception Risk

Healthcare companies operate in sensitive areas involving drug costs, patient access, and provider relationships. Acquisitions can draw criticism if stakeholders fear higher costs or reduced independence.

Case Studies of Major McKesson Acquisitions

HBO & Company

HBO & Company was McKesson’s largest listed acquisition, valued at $14.1 billion. The company made clinical, financial, billing, physician practice, and medical records software.

This acquisition represented a major bet on healthcare information systems. It showed McKesson’s ambition to move beyond distribution and become a bigger player in healthcare technology.

The deal remains a defining moment in McKesson’s M&A history because of its scale and its focus on healthcare software.

Celesio

Celesio was acquired for $5.4 billion in 2013. The company provided pharmaceutical logistics and services across 16 countries.

This acquisition expanded McKesson’s international reach and strengthened its pharmaceutical distribution capabilities. It was one of the company’s most important global expansion moves.

Celesio also reflected the importance of scale in pharmaceutical logistics.

Core Ventures

Core Ventures was announced in 2024 at about $2.49 billion for a 70% controlling interest. The organization was established by Florida Cancer Specialists & Research Institute to provide business and administrative services. McKesson completed the acquisition in June 2025, with Florida Cancer Specialists physicians retaining about 30%.

This acquisition strengthened McKesson’s oncology platform and connected Core Ventures with The US Oncology Network. It also showed McKesson’s continued interest in community oncology.

US Oncology

US Oncology was acquired for $2.1 billion in 2010. The company operated a network of integrated community-based oncology practices in the United States.

This acquisition was central to McKesson’s oncology strategy. It gave the company deeper access to cancer care delivery, provider networks, specialty drugs, and community oncology operations.

CoverMyMeds

CoverMyMeds was acquired for $1.1 billion in 2017. The platform helps doctors and pharmacists complete prior authorization and insurance coverage determination forms for drugs.

The deal strengthened McKesson’s healthcare software presence and addressed a major source of friction in prescription access. Prior authorization can delay medication access, so a platform that streamlines the process has strategic value.

Common Mistakes When Analyzing McKesson Acquisitions

Treating McKesson as Only a Drug Distributor

McKesson is a major distributor, but its acquisitions show a broader business model that includes healthcare software, oncology, pharmacy services, medical supplies, and administrative support.

Ignoring Oncology

Oncology is one of the clearest themes in McKesson’s acquisition history. US Oncology, Biologics, Vantage Oncology, Oncology Therapeutics Network, and Core Ventures all point to this priority.

Looking Only at Deal Size

Large deals matter, but smaller acquisitions such as Medcon, Moore Medical, and MediVation added important capabilities in specialized healthcare technology and distribution.

Overlooking Regulatory Risk

Healthcare M&A is heavily influenced by regulation. Analysts should consider antitrust, reimbursement policy, drug pricing, provider independence, and patient access concerns.

Confusing Revenue Scale With Strategic Control

McKesson’s acquisitions are not only about adding revenue. They also expand influence over workflows, networks, patient access, and healthcare infrastructure.

Lessons for Business Owners and Investors

McKesson’s acquisition history offers several lessons.

First, distribution businesses can become platforms. McKesson expanded from product movement into technology, services, and specialty care infrastructure.

Second, healthcare software can be strategically powerful. Platforms such as CoverMyMeds and Rx Savings Solutions solve workflow and affordability problems that affect many parts of healthcare.

Third, specialty care matters. Oncology acquisitions show how complex therapeutic areas can become central to healthcare strategy.

Fourth, scale is important, but integration is critical. Large healthcare acquisitions can create value only if systems, teams, compliance, and customer relationships are managed well.

Finally, healthcare M&A requires stakeholder awareness. Patients, providers, regulators, employers, pharmacies, and drug manufacturers all have interests in how these deals affect access, cost, and care quality.

Key Takeaways

• McKesson completed 21 acquisitions from 1990 to 2024.
• Total disclosed deal value was about $36.1 billion.
• The average disclosed acquisition size was approximately $1.7 billion.
• Health care was the most common category, with 13 deals.
• Pharmaceutical businesses accounted for 6 acquisitions.
• Software accounted for 5 acquisitions.
• The largest listed acquisition was HBO & Company at $14.1 billion.
• Celesio was the second-largest listed acquisition at $5.4 billion.
• Core Ventures was announced in 2024 for about $2.49 billion for a controlling interest.
• McKesson’s acquisition strategy focuses heavily on oncology, pharmacy services, healthcare software, medical supplies, and pharmaceutical distribution.
• Key risks include regulation, integration complexity, healthcare policy changes, large-deal execution, and public perception.
• McKesson acquisitions show how healthcare distribution can evolve into a broader services and technology platform.

Frequently Asked Questions

What are McKesson acquisitions?

McKesson acquisitions are companies or business interests acquired by McKesson to expand its healthcare distribution, pharmaceutical, oncology, software, medical supplies, and care management businesses.

How many acquisitions has McKesson made?

McKesson has made 21 acquisitions across the period from 1990 to 2024.

What is the total value of McKesson acquisitions?

The total disclosed value of McKesson acquisitions is about $36.1 billion.

What is McKesson’s average acquisition size?

McKesson’s average disclosed acquisition size is approximately $1.7 billion.

What was McKesson’s most recent listed acquisition?

The most recent listed acquisition is Core Ventures, announced in August 2024 for about $2.5 billion. McKesson later said the transaction closed in June 2025.

What is McKesson’s biggest listed acquisition?

The biggest listed McKesson acquisition is HBO & Company, announced in 1998 for $14.1 billion.

Which sectors does McKesson focus on?

McKesson acquisitions focus mainly on health care, pharmaceuticals, software, medical services, information technology, oncology, pharmacy services, and medical supply distribution.

Why did McKesson acquire Core Ventures?

McKesson acquired a controlling interest in Core Ventures to strengthen its oncology platform and expand administrative support connected to Florida Cancer Specialists and The US Oncology Network.

Why are oncology acquisitions important to McKesson?

Oncology is important because it involves specialty drugs, complex care coordination, patient support, provider networks, and high-cost treatments. McKesson has made several acquisitions in this area.

What are the risks of McKesson’s acquisition strategy?

The main risks include regulatory scrutiny, integration challenges, healthcare policy changes, drug pricing pressure, public perception, and execution risk on large acquisitions.

Conclusion

McKesson acquisitions show how a healthcare distribution company can use M&A to become a broader healthcare services and technology platform. From 1990 to 2024, McKesson completed 21 acquisitions with total disclosed deal value of about $36.1 billion. Its acquisition strategy has focused on health care, pharmaceuticals, software, medical supplies, oncology, pharmacy services, and care management.

The company’s largest deals tell the story clearly. HBO & Company expanded healthcare software. Celesio expanded international pharmaceutical logistics. US Oncology, Vantage Oncology, Biologics, and Core Ventures strengthened oncology. CoverMyMeds and Rx Savings Solutions added software platforms tied to medication access and affordability.

For business owners, investors, and healthcare analysts, McKesson acquisitions offer a major lesson: healthcare value is shifting toward integrated platforms that connect products, providers, patients, data, reimbursement, and administration. McKesson’s M&A strategy reflects that shift, but it also carries the challenges that come with healthcare scale, regulation, public scrutiny, and complex integration.

Disclaimer: This article is for informational and educational purposes only. It is not investment advice, financial advice, or a recommendation to buy or sell any security. Always conduct your own research and consider speaking with a qualified financial adviser before making investment decisions.

Read Also: MBK Partners Acquisitions: How MBK Built Its Business Through M&A